cleenema klar-til-brug rektalvæske, opløsning
casen recordati, s.l. - dinatriumphosphatdihydrat, natriumdihydrogenphosphat dihydrat - rektalvæske, opløsning
cleenema klar-til-brug rektalvæske, opløsning
2care4 aps - dinatriumphosphatdihydrat, natriumdihydrogenphosphat dihydrat - rektalvæske, opløsning
cleen klar-til-brug rektalvæske, opløsning
orifarm a/s - dinatriumphosphatdihydrat, natriumdihydrogenphosphat dihydrat - rektalvæske, opløsning
fosfat "sad" rektalvæske, opløsning, enkeltdosisbeholder
amgros i/s - dinatriumphosphatdihydrat, natriumdihydrogenphosphat dihydrat - rektalvæske, opløsning, enkeltdosisbeholder
biphozyl hæmodialyse-/hæmofiltreringsvæske
baxter holding b.v. - dinatriumphosphatdihydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumhydrogencarbonat - hæmodialyse-/hæmofiltreringsvæske
pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiske midler - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
alatopran 5 mg/ml+50 mikrog/ml øjendråber, opløsning
actavis group ptc ehf. - latanoprost, timololmaleat - øjendråber, opløsning - 5 mg/ml+50 mikrog/ml
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiske midler - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
phosphoral oral opløsning
casen recordati, s.l. - dinatriumphosphat, phosphorsyre, koncentreret - oral opløsning
phosphoral oral opløsning
2care4 aps - dinatriumphosphat, vandfri, phosphorsyre, koncentreret - oral opløsning